Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15829331rdf:typepubmed:Citationlld:pubmed
pubmed-article:15829331lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15829331lifeskim:mentionsumls-concept:C0812413lld:lifeskim
pubmed-article:15829331lifeskim:mentionsumls-concept:C0039736lld:lifeskim
pubmed-article:15829331pubmed:issue2lld:pubmed
pubmed-article:15829331pubmed:dateCreated2005-4-14lld:pubmed
pubmed-article:15829331pubmed:abstractTextThe purpose of this study was to describe the experience with the anti-angiogenic agent thalidomide in the treatment of patients with a malignant pleural mesothelioma (MPM).lld:pubmed
pubmed-article:15829331pubmed:languageenglld:pubmed
pubmed-article:15829331pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15829331pubmed:citationSubsetIMlld:pubmed
pubmed-article:15829331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15829331pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15829331pubmed:statusMEDLINElld:pubmed
pubmed-article:15829331pubmed:monthMaylld:pubmed
pubmed-article:15829331pubmed:issn0169-5002lld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:BaasPaulPlld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:BoogerdWillem...lld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:DalesioOtilia...lld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:HaringhuizenA...lld:pubmed
pubmed-article:15829331pubmed:authorpubmed-author:CustersFrankFlld:pubmed
pubmed-article:15829331pubmed:issnTypePrintlld:pubmed
pubmed-article:15829331pubmed:volume48lld:pubmed
pubmed-article:15829331pubmed:ownerNLMlld:pubmed
pubmed-article:15829331pubmed:authorsCompleteYlld:pubmed
pubmed-article:15829331pubmed:pagination291-6lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:meshHeadingpubmed-meshheading:15829331...lld:pubmed
pubmed-article:15829331pubmed:year2005lld:pubmed
pubmed-article:15829331pubmed:articleTitleThalidomide in patients with malignant pleural mesothelioma.lld:pubmed
pubmed-article:15829331pubmed:affiliationDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. p.baas@nki.nllld:pubmed
pubmed-article:15829331pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15829331pubmed:publicationTypeClinical Triallld:pubmed